China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Google Secures Pentagon AI Deal for Classified Projects 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
CAMBRIDGE, Mass., Feb. 03, 2016 -- SAGE Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will present at the 2016 Leerink Global Healthcare Conference at 3:55 PM ET on Wednesday, February 10, 2016, in New York City.
A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. Sage is developing its next generation modulators, including SAGE-217, SAGE-689 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.
Investor Contact: Paul Cox, Sage Therapeutics [email protected] 617-299-8377 Media Contact: Maureen L. Suda, Suda Communications LLC [email protected] 585-387-9248
